FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387194310> ?p ?o ?g. }

• W4387194310 endingPage "153" @default.
• W4387194310 startingPage "146" @default.
• W4387194310 abstract "Aim. To describe the methods of drug therapy implemented for the disease control in patients with polycythemia vera (PV) and myelofibrosis (MF) as well as to analyze manifestations and severity of the disease symptoms in real-world clinical practice.&#x0D; Materials & Methods. The analysis focused on the data of 1229 patients. In 629 (51.18 %) patients, PV was diagnosed, MF was identified in 521 (42.39 %) patients. The diagnosis of 79 (6.43 %) patients was not reported. Early stage of primary MF (PMF) was detected in 182 (34.93 %) patients, PMF fibrosis stage was identified in 251 (48.18 %) patients, post-polycythemic MF was registered in 61 (11.71 %) patients, and 13 (2.5 %) patients showed post-thrombocythemic MF. In 14 (2.69 %) patients, MF type was not reported. By the time of diagnosis, the median age of PV patients was 56 years (range 17–86 years), and that of MF patients was 55 years (range 16–83 years) (p = 0.022). The proportion of women among PV patients was 57 %, among MF patients it was 65 % (p = 0.0065).&#x0D; Results. The assessment of thrombotic complication risk in PV showed that 51.01 % (n = 302) of patients belong to the low-risk, 39.86 % (n = 236) belong to the intermediate-risk, and only 9.12 % (n = 54) of patients belong to the high-risk groups. Distribution of MF patients between risk groups demonstrates favorable prognosis for most patients. The group of low and intermediate-1 risks includes 56.43 % (n = 294) patients according to the prognostic scoring system IPSS and 68.52 % (n = 357) according to the prognostic scoring system DIPSS. In the vast majority of cases, patients received hydroxycarbamide therapy: 81.81 % (n = 832) in the total cohort, 83.33 % (n = 465) in the PV group, and 79.96 % (n = 367) in the MF group. Interferon-α was administered to 19.71 % (n = 110) of PV patients and 29.85 % (n = 137) of MF patients. Ruxolitinib was assigned to 3.14 % (n = 19) of PV patients and 21.35 % (n = 98) of MF patients.&#x0D; Conclusion. Regular monitoring of the PV and MF course and treatment efficacy can provide recommendations for adequate change of therapy in case of the failure of previous treatment. It should be emphasized that the timely switch to the second-line therapy results in reduced disability and mortality among PV and MF patients with myeloproliferative neoplasms." @default.
• W4387194310 created "2023-09-30" @default.
• W4387194310 creator A5001441538 @default.
• W4387194310 creator A5006689687 @default.
• W4387194310 creator A5008276842 @default.
• W4387194310 creator A5014794168 @default.
• W4387194310 creator A5018301734 @default.
• W4387194310 creator A5036941945 @default.
• W4387194310 creator A5042688424 @default.
• W4387194310 creator A5043860169 @default.
• W4387194310 creator A5049820881 @default.
• W4387194310 creator A5052059313 @default.
• W4387194310 creator A5053886367 @default.
• W4387194310 creator A5066402945 @default.
• W4387194310 creator A5066916600 @default.
• W4387194310 creator A5067477995 @default.
• W4387194310 creator A5073030789 @default.
• W4387194310 creator A5082162280 @default.
• W4387194310 creator A5084129424 @default.
• W4387194310 creator A5090837936 @default.
• W4387194310 creator A5092970738 @default.
• W4387194310 creator A5092970739 @default.
• W4387194310 creator A5092970740 @default.
• W4387194310 date "2023-03-03" @default.
• W4387194310 modified "2023-10-18" @default.
• W4387194310 title "Approaches to the Treatment of Patients with Myelofibrosis and Polycythemia Vera with Constitutional Symptoms in Real-World Clinical Practice in the Russian Federation: Intermediate Results of a Multi-Center Observational Prospective Clinical Study" @default.
• W4387194310 doi "https://doi.org/10.21320/2500-2139-2023-16-2-146-153" @default.
• W4387194310 hasPublicationYear "2023" @default.
• W4387194310 type Work @default.
• W4387194310 citedByCount "0" @default.
• W4387194310 crossrefType "journal-article" @default.
• W4387194310 hasAuthorship W4387194310A5001441538 @default.
• W4387194310 hasAuthorship W4387194310A5006689687 @default.
• W4387194310 hasAuthorship W4387194310A5008276842 @default.
• W4387194310 hasAuthorship W4387194310A5014794168 @default.
• W4387194310 hasAuthorship W4387194310A5018301734 @default.
• W4387194310 hasAuthorship W4387194310A5036941945 @default.
• W4387194310 hasAuthorship W4387194310A5042688424 @default.
• W4387194310 hasAuthorship W4387194310A5043860169 @default.
• W4387194310 hasAuthorship W4387194310A5049820881 @default.
• W4387194310 hasAuthorship W4387194310A5052059313 @default.
• W4387194310 hasAuthorship W4387194310A5053886367 @default.
• W4387194310 hasAuthorship W4387194310A5066402945 @default.
• W4387194310 hasAuthorship W4387194310A5066916600 @default.
• W4387194310 hasAuthorship W4387194310A5067477995 @default.
• W4387194310 hasAuthorship W4387194310A5073030789 @default.
• W4387194310 hasAuthorship W4387194310A5082162280 @default.
• W4387194310 hasAuthorship W4387194310A5084129424 @default.
• W4387194310 hasAuthorship W4387194310A5090837936 @default.
• W4387194310 hasAuthorship W4387194310A5092970738 @default.
• W4387194310 hasAuthorship W4387194310A5092970739 @default.
• W4387194310 hasAuthorship W4387194310A5092970740 @default.
• W4387194310 hasBestOaLocation W43871943101 @default.
• W4387194310 hasConcept C126322002 @default.
• W4387194310 hasConcept C141071460 @default.
• W4387194310 hasConcept C146357865 @default.
• W4387194310 hasConcept C151730666 @default.
• W4387194310 hasConcept C2777753580 @default.
• W4387194310 hasConcept C2778837598 @default.
• W4387194310 hasConcept C2779134260 @default.
• W4387194310 hasConcept C2780007613 @default.
• W4387194310 hasConcept C2780076729 @default.
• W4387194310 hasConcept C71924100 @default.
• W4387194310 hasConcept C81182388 @default.
• W4387194310 hasConcept C86803240 @default.
• W4387194310 hasConcept C90924648 @default.
• W4387194310 hasConceptScore W4387194310C126322002 @default.
• W4387194310 hasConceptScore W4387194310C141071460 @default.
• W4387194310 hasConceptScore W4387194310C146357865 @default.
• W4387194310 hasConceptScore W4387194310C151730666 @default.
• W4387194310 hasConceptScore W4387194310C2777753580 @default.
• W4387194310 hasConceptScore W4387194310C2778837598 @default.
• W4387194310 hasConceptScore W4387194310C2779134260 @default.
• W4387194310 hasConceptScore W4387194310C2780007613 @default.
• W4387194310 hasConceptScore W4387194310C2780076729 @default.
• W4387194310 hasConceptScore W4387194310C71924100 @default.
• W4387194310 hasConceptScore W4387194310C81182388 @default.
• W4387194310 hasConceptScore W4387194310C86803240 @default.
• W4387194310 hasConceptScore W4387194310C90924648 @default.
• W4387194310 hasIssue "2" @default.
• W4387194310 hasLocation W43871943101 @default.
• W4387194310 hasOpenAccess W4387194310 @default.
• W4387194310 hasPrimaryLocation W43871943101 @default.
• W4387194310 hasRelatedWork W1978226762 @default.
• W4387194310 hasRelatedWork W2101002658 @default.
• W4387194310 hasRelatedWork W2304558087 @default.
• W4387194310 hasRelatedWork W2555199111 @default.
• W4387194310 hasRelatedWork W2559675553 @default.
• W4387194310 hasRelatedWork W2620415343 @default.
• W4387194310 hasRelatedWork W2810060832 @default.
• W4387194310 hasRelatedWork W2970123554 @default.
• W4387194310 hasRelatedWork W4294630148 @default.
• W4387194310 hasRelatedWork W89167677 @default.
• W4387194310 hasVolume "16" @default.
• W4387194310 isParatext "false" @default.
• W4387194310 isRetracted "false" @default.
• W4387194310 workType "article" @default.